主页 > 生命科学 >
【medical-news】联合声明建议植入DES者延长抗血小
17 January 2007
Five medical societies have entered the debate on drug-eluting stents (DES), issuing a joint statement recommending that dual antiplatelet therapy is continued for at least one year after stent placement.
The societies involved include the American Heart Association, the American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, the American College of Surgeons, and the American Dental Association. The American College of Physicians was represented in the document but has not officially endorsed it.
"We want to alert patients and healthcare professionals that this is a serious medical issue; they shouldn't even think about stopping antiplatelet therapy because it could result in heart attack or death," commented Cindy Grines (William Beaumont Hospital, Royal Oak, Missouri, USA), chair of the advisory writing committee.
The Science Advisory, which appears in an advance online publication by the journal Circulation, also discusses different types of stents, noting that DES are both "good and bad". The paper says that stent thrombosis is the "leading adverse event" associated with early antiplatelet discontinuation in patients with DES and carries a mortality rate of 20–45%.
The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy. These include discussing the issue with patients before stent implantation; using bare metal stents in patients likely to need surgery within the next 12 months; delaying elective procedures until an appropriate course of antiplatelet therapy has been completed; and restarting therapy as soon as possible if it has to be temporarily discontinued.
Finally, the committee urges the healthcare industry to ensure that "issues such as drug cost" do not cause patients to discontinue their medication prematurely with "catastrophic cardiovascular consequences".
Circulation 2007; Advance online publication
http://www.incirculation.net/NewsItem/Joint-statement-urges-prolonged-antiplatelet-thera.aspx 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Joint statement urges prolonged antiplatelet therapy with DES
联合声明建议植入DES者延长抗血小板治疗时间
17 January 2007
2007年1月17日
Five medical societies have entered the debate on drug-eluting stents (DES), issuing a joint statement recommending that dual antiplatelet therapy is continued for at least one year after stent placement.
五个医学协会对药物洗脱支架讨论后，提出了了一项联合声明，建议至少应当持续应用抗血小板治疗直到支架放置一年之后。
The societies involved include the American Heart Association, the American College of Cardiology, the Society for Cardiovascular Angiography and Interventions, the American College of Surgeons, and the American Dental Association. The American College of Physicians was represented in the document but has not officially endorsed it.
这些协会包括美国心脏病协会，美国心脏病学会，心血管造影和介入协会，美国外科学会和美国牙科协会。美国内科学会只在文件上代表参与，并没有官方正式署名。
"We want to alert patients and healthcare professionals that this is a serious medical issue; they shouldn't even think about stopping antiplatelet therapy because it could result in heart attack or death," commented Cindy Grines (William Beaumont Hospital, Royal Oak, Missouri, USA), chair of the advisory writing committee.
声明纂写委员会主席，美国密苏里William Beaumont医院Cindy Grines说：“我们想提醒患者和医疗保健专家们这是个严肃的医学问题，他们甚至不应该考虑停止抗血小板治疗因为这会导致心脏病发作或者死亡。”
The Science Advisory, which appears in an advance online publication by the journal Circulation, also discusses different types of stents, noting that DES are both "good and bad". The paper says that stent thrombosis is the "leading adverse event" associated with early antiplatelet discontinuation in patients with DES and carries a mortality rate of 20–45%.
《循环》杂志提前在线刊物中的科学咨询也讨论了不同种类的支架，同时提到药物洗脱支架有利也有弊。这篇文章中说，对于药物洗脱支架置入的患者，支架内血栓形成是和早期停用抗血小板紧密相关的主要副作用，其死亡率为20％到50％。
The report makes a number of practical recommendations to eliminate early discontinuation of antiplatelet therapy. These include discussing the issue with patients before stent implantation; using bare metal stents in patients likely to need surgery within the next 12 months; delaying elective procedures until an appropriate course of antiplatelet therapy has been completed; and restarting therapy as soon as possible if it has to be temporarily discontinued.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-09-08 05:12
医学,生命科学网